Anaerobic infections: Update on treatment considerations

Research output: Contribution to journalReview article

41 Citations (Scopus)


Anaerobic bacteria are the predominant indigenous flora of humans and, as a result, play an important role in infections, some of which are serious with a high mortality rate. These opportunistic pathogens are frequently missed in cultures of clinical samples because of shortcomings in collection and transport procedures as well as lack of isolation and susceptibility testing of anaerobes in many clinical microbiology laboratories. Correlation of clinical failures with known antibacterial resistance of anaerobic bacteria is seldom possible. Changes in resistance over time, and the discovery and characterization of resistance determinants in anaerobic bacteria, has increased recognition of problems in empirical treatment and has even resulted in changes in treatment guidelines. This review discusses the role of anaerobic bacteria in the normal flora of humans, their involvement in different mixed infections, developments in antibacterial resistance of the most frequent anaerobic pathogens and possible new treatment options.

Original languageEnglish
Pages (from-to)841-858
Number of pages18
Issue number7
Publication statusPublished - May 7 2010



  • Anaerobic-infections, treatment
  • Carbapenems, therapeutic use
  • Cephamycins, therapeutic use
  • Clindamycin, therapeutic use
  • Metronidazole, therapeutic use
  • Moxifloxacin, therapeutic use
  • Piperacillintazobactam, therapeutic use
  • Tigecycline, therapeutic use

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this